MDSF Center of Excellence, Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, is conducting a study on high dose vitamin C and its effect on the TET2 mutation in patients with MDS. Vitamin C may “tell” faulty stem cells in the bone marrow to mature and die normally, instead of multiplying to cause blood cancers. Certain genetic changes are known to reduce the ability of an enzyme called TET2 to encourage stem cells to become mature blood cells, which eventually die, in many patients with certain kinds of leukemia and MDS, say the authors. This new study found that vitamin C activated TET2 function in mice engineered to be deficient in the enzyme.
The team at Perlmutter Cancer Center hopes that high doses of vitamin C will eventually be incorporated into cancer therapies. Vitamin C in combination with cancer drugs may provide an alternative approach.
Would you like to participate in this clinical trial?
You may be eligible for this study if you meet the following criteria:
Conditions:
- Myelodysplastic Syndrome
- Between 18 – 99 Years
- Male or Female
Other Inclusion Criteria:
- Histologically confirmed Myelodysplastic Syndrome with positive TET2 mutations
- Myeloblasts account for less than 20% of leukocytes on peripheral blood and bone marrow aspirate
- Adequate organ function
You may not be eligible for this study if the following are true:
- Any cancer-related therapy for the current disease within 2 weeks of screening
- Requirement for systemic immunosuppressive therapy
- Uncontrolled concurrent serious illness
If you are interested, please contact the MDSF or the Center of Excellence directly (Dr. Raoul Tibes via email at Raoul.Tibes@nyulangone.org).
